Recap: Dyne Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Dyne Therapeutics (NASDAQ:DYN) reported Q4 earnings with an EPS of $-1.09, missing estimates by -18.0% and showing no revenue change from the previous year. The company had previously missed EPS estimates last quarter, resulting in a 4.0% share price drop the following day.
March 05, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Dyne Therapeutics reported a significant miss in Q4 earnings with an EPS of $-1.09, underperforming against estimates by 18%, and showed no revenue growth from the previous year.
The significant miss in earnings estimates and the lack of revenue growth are likely to negatively impact investor sentiment towards DYN in the short term. Historical context from the previous quarter shows a direct correlation between earnings misses and subsequent share price drops, suggesting a potential repeat of this pattern.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100